Literature DB >> 33680886

Frequency of Sperm Aneuploidy in Oligoasthenoteratozoospermic (OAT) Patients by Comprehensive Chromosome Screening: A Proof of Concept.

Parishad Saei1,2, Masood Bazrgar1, Hamid Gourabi1, Roxana Kariminejad3, Poopak Eftekhari-Yazdi4, Mostafa Fakhri1.   

Abstract

BACKGROUND: Embryonic aneuploidy usually results in implantation failure and miscarriage. Considering significantly high frequency of sperm aneuploidy reported in oligoasthenoteratozoospermia (OAT) using fluorescence in situ hybridization (FISH) in limited number of chromosomes and lack of comprehensive chromosome screening (CCS) in OAT, the aim of this study was applying CCS in OAT sperm and comparison of the results with FISH findings.
METHODS: Five OAT patients with normal blood karyotypes and history of implantation failure were included. The successfully amplified samples, each containing two sperm, were analyzed by array comparative genomic hybridization (aCGH). FISH was utilized mainly depending on the aneuploidies found by aCGH to assess their frequencies in total sperm population.
RESULTS: In aCGH for 30 sperm, aneuploidy was found in 66% of samples. Following the study of 4300 sperm by FISH, an average of 55.46% aneuploidy was observed. No pregnancy was resulted with normal partners.
CONCLUSION: Using aCGH, some abnormalities were observed that are not typically considered in sperm FISH studies. Despite small sample size of the comprehensive study, like other similar studies, the frequency of aneuploidies was considerable and similar to FISH. Aneuploidies revealed by aCGH at single sperm resolution were different from sperm population detected by FISH. Considering high frequency of aneuploidy in OATs sperm, preimplantation genetic testing for aneuploidy (PGT-A) can be used for in transfer of chromosomally normal embryos. Copyright
© 2021, Avicenna Research Institute.

Entities:  

Keywords:  Aneuploidy; Array comparative genomic hybridization; Fluorescence; In situ hybridization; Oligospermia; Spermatozoa

Year:  2021        PMID: 33680886      PMCID: PMC7903664          DOI: 10.18502/jri.v22i1.4996

Source DB:  PubMed          Journal:  J Reprod Infertil        ISSN: 2228-5482


Introduction

Fertility problems affect 60–80 million couples worldwide according to WHO estimations and approximately half of these problems are due to a male factor (1). Aneuploidy as a numerical chromosome abnormality is considered one of the main causes of pregnancy loss (2). Maternal parameters such as age and meiotic defects are associated with production of chromosomally abnormal embryo and reduced quality of embryo (3); however, scarce information is available on the role of paternal factors. Total aneuploidy of 4.5% was calculated in normozoospermic males based on common studies that employed fluorescence in situ hybridization (FISH) (4). Men with abnormal seminal parameters but normal karyotype carry more chromosomal aberrations such as malsegregation; interestingly, their sperm aneuploidy rate is higher than normal or infertile men with normal spermatozoa (5). According to various studies conducted in the field of sperm aneuploidy in individuals with different phenotypes of infertility (Oligozoospermia, asthenozoospermia and teratozoospermia), there is a significantly high incidence of aneuploidy in spermatozoa from severely oligoasthenoteratozoospermic (OAT) patients (6, 7) compared to moderate OAT subjects (11). OAT patients have lower rate of gestation and implantation after intra cytoplasmic sperm injection (ICSI) treatment (8–10). FISH as a commonly used method to detect aneuploidy has facilitated examination of sperm in severe male factor infertility. Different rates of total aneuploidy have been reported due to different and limited number of chromosomes studied as one of the major problems of using FISH for comprehensive study of aneuploidy. Few studies have employed aCGH for sperm aneuploidy assessment in a single sperm case (11, 12). The development of a comprehensive tool and the accurate assessment of all chromosomes would allow us to improve our understanding on the pathophysiology of spermatogenesis. It estimate the paternally derived aneuploidy risk and hence better manage the high risk in patients for transmitting chromosomal abnormalities during in vivo or in vitro conception. According to FISH findings, due to limited number of chromosomes in OAT and lack of simultaneous evaluation of all chromosomes in OAT patients, this proof of concept was designed to better evaluate the contribution of aneuploidy in OAT. Comprehensive aneuploidy screening was applied in spermatozoa collected from these subjects at single sperm resolution by aCGH as a powerful technique for aneuploidy detection and the results were compared with those obtained by FISH findings in total sperm population of the same subjects.

Methods

The protocols used in this study were approved by Institutional Review Board and informed consent was obtained from all the patients after approval of the study by the Institutional Ethics Committee. Fresh semen samples were collected from five infertile men with severe OAT. All the subjects had sperm concentrations <5 million/ml, total motility <40% and severe teratozoospermia with 0–1% normal forms according to WHO guidelines (2010); the patients were referred for treatment of infertility and underwent ICSI. They had normal blood karyotypes and a history of implantation failure. Patients with Y chromosome microdeletions, chemotherapy, exposure to toxicity, high temperature, varicocele, genitourinary infections, malignancy and sex hormones alterations were excluded from the study. Female partners were reproductively healthy and <36 years old. The history and characteristics of couples and semen parameters are summarized in table 1.
Table 1.

Characteristics and semen parameters of OAT patients

PatientsAgeInfertility duration (year)Implantation failure (cycles)Volume (ml)Sperm concentration ×106/mlTotal motility (%)Normal morphology (%)
P13810.513.52101
P2362124301
P3336421.5–210–150–1
P436811.53101
P5357230.012–30
Characteristics and semen parameters of OAT patients A part of all semen specimens was used for ICSI and the remainder was employed for aCGH analysis and FISH. A small aliquot of semen was rinsed two times in Ham’s F10 medium and centrifuged at 2700 rpm for 5 min. A pellet of almost 2 μl was placed into a polyvinylpyrrolidone (PVP) drop for immobilization and convenient handling of sperm; then, 2 spermatozoa were aspirated and transferred to 0.2 ml PCR tube in a drop containing 2 μl of sterile phosphate-buffered saline (PBS) without calcium and magnesium (Gibco, UK). 4 samples were prepared for each patient. Whole Genome Amplification was conducted according to 24 sure V3 protocol. Decondensation was performed as previously described (13) using proteinase K and dithiothreitol (DTT) between two steps of extraction and pre-amplification. Samples were loaded on 1% agarose gel and those with successful amplification were analyzed by 24 sure illumina platform aCGH protocol according to manufacturer’s instructions. The images of hybridization were scanned by a laser scanner (InnoScan 710, Innopsys, France), then analyzed by BlueFuse Multi Software version 4.1. Semen samples were prepared by washing according to a previously described protocol (16). Double or triple color FISH was used with 10–11 relevant probes (Vysis, USA), mainly based on aneuploidies found by aCGH, to compare the results of single sperm aCGH with total sperm population. For each subject, probes were added to the parts of the slides with suitable density as indicated in supplementary table 1. FISH was performed using the protocol introduced by the manufacturer (Vysis, USA).
Supplementary table 1.

Representative chromosomes assessed by FISH and specified probes for each subject

SubjectsStudied chromosomesProbes
P1
X, Y, 21CEP X (DXZ1), CEP Y (DYZ1), LSI 21q22.1–22.2
5, 18TEL 5q, CEP 18
14, 18TEL 14q, CEP 18
19, 22TEL 19q, LSI 22q11.2
8, 13CEP 8, LSI 13q14
P2
X, Y, 18CEP X, CEP Y(DYZ3), CEP 18
3, 8CEP 3, CEP 8
3, 16CEP 3, CEP 16
9, 13, 14CEP 9, LSI 13, TEL 14q
11, 13, 21CEP 11, LSI 13, LSI 21
P3
X, Y, 21CEP X, CEP Y, LSI 21
11, 12CEP 11, CEP 12
17, 22CEP 17, LSI 22
7, 13, 21CEP 7, LSI 13, LSI 21
10, 12, 20CEP 10, CEP 12, CEP 20
P4
X, Y, 21CEP X, CEP Y, LSI 21
19, 22TEL 19, LSI 22
13, 18, 21LSI 13, CEP 18, LSI 21
10, 12, 20CEP 10, CEP 12, CEP 20
P5
X, Y, 21CEP X, CEP Y, LSI 21
8, 22CEP 8, LSI 22
13, 18, 21LSI 13, CEP 18, LSI 21
10, 12, 20CEP 10, CEP 12, CEP 20

CEP: Centromeric probe (chromosome enumeration probe), TEL: Telomeric probe, and LSI: Locus-specific identifier probe

Only spermatozoa with clear signals were analyzed. Two completely separate spots in one spermatozoon were considered disomy and if there was no signal, nullisomy was accounted. However, if nullisomy was observed in all chromosomes examined in a slide, it was not scored due to the probable lack of hybridization. Overlapped cells with doubtful signals were also ignored.

Results

The age of our patients ranged from 33 to 38 years with 2–10.5 years of infertility and 1–4 cycles of implantation failure, as mentioned in table 1. Totally, 15 out of 20 samples had successful amplification and good quality for aCGH, which were included in aCGH data analysis. A wide range of abnormalities was found in OAT sperm by aCGH. Aneuploidy was detected in 66% of samples ranging from 1 to 6 chromosomes per patient. Multiple aneuploidy was seen in 26.6% of samples. In total, sex chromosome disomy and trisomy were detected in 26.6% of samples. Also, 33.3% of samples were found to be normal. Next, those abnormal chromosomes for FISH with more possibility to involvement of entire chromosome were nominated, mainly according to aCGH findings. The results of aCGH data analysis for all patients and some genomic profile examples are presented in table 2 and figure 1, respectively. In FISH analyses, a total of 4300 sperm nuclei and between 400–1286 sperm per subject with reliable signals were analyzed depending on the volume of semen, sperm depositions and the number of prepared slides. Totally, 19 chromosomes, (10–11 chromosome per patient), were analyzed in this study. Total aneuploidy was 38.25–81.6% with an average of 55.46%. The frequencies of disomy and nullisomy for autosomes and sex chromosome aneuploidy are displayed in supplementary table 2. Despite high fertilization rate and transfer of 2–3 good quality embryos, none of our studied patients had pregnancy after ICSI (Supplementary table 3).
Table 2.

Array CGH analysis results of OAT patients

SubjectsSamples (total=15)Chromosomes

GainLoss
P1
14, 5, 8, 193, 6, 14, 21
21416, 21, 22
3--
P2
16, 8, 9, 10, 16, 181, 11, 13, 14, 17, 20, 21
23, 8, 10, 13, 16, 211, 9, 11, 18
P3
16, 7, 8, 11, 122, 10, 17, 21
2--
320-
P4
119, X-
219, X-
319, X, Y-
P5
1--
2--
3--
4Y-
Figure 1.

Array CGH profiles of OAT patients (A–D) and different types of aneuploidy in OAT sperm population as assessed by FISH (E–G). A) A genomic profile with complex abnormality for chromosomes −1+3+8–9+10–11+ 13+ 16–18+21 in patient 2. B) Single chromosomal aneuploidy of +20 in patient 3. C) A genomic profile with sex chromosome aneuploidy (Gain of Y) in patient 5. D) A genomic profile with gain of chromosome 19 and sex chromosome aneuploidy (Gain of X/Y) in patient 4. E) Right, a sperm with three signals for chromosome 3 (Red) and normal signal for chromosome 16 (Aqua) and left, a normal sperm with single signals for both chromosomes in patient 2. F) Double disomy for chromosomes 12 (Green) and 20 (Red) and normal signal for chromosome 10 in patient 3. G) Disomy for chromosome 10 (Aqua) and normal signals for chromosomes 12 (Green) and 20 (Red) in patient 3

Supplementary table 2.

Frequency of disomy and nullisomy in autosomes and sex chromosomes in OAT patients

SubjectAnalyzed cellsChromosomes abnormality rate%
35789101112131416171819202122XYXXYYXXYXYYXXYYTotal
Autosomal and gonosomal disomy%P17262.51.72.34.70.880.83.52.42.50.5200.5023.78
P212863.62.81.41.0130.721.54.73.2500.60.30.6037.52
P37821.20.41.33.314.52.210.34.68.86.41.10.80.80.8054.9
P411001.24.55.22.62.622.62.65.41.20.80.600.230.7
P54003.32.34.61.56.02.35.22.57.21.62.40.81.6033.7
Mean3.62.51.22.61.41.31.154.137.32.711.52.23.51.74.93.94.15.30.91.30.50.70.2036.12

Autosomal and gonosomal nullisomy%P17260.90.60.03.770.41.63.03.70.514.47
P212862.80.72.91.11.21.43.72.34.93.024
P37822.46.90.71.32.44.41.76.30.01.126.7
P411002.351.81.91.30.51.25.21.51.116.85
P54000.02.30.04.51.50.03.91.70.814.7
Mean2.80.52.40.652.93.90.91.551.42.53.74.41.31.01.54.61.71.419.34
Supplementary table 3.

Intracytoplasmic sperm injection (ICSI) outcomes of studied OAT patients

P1P2P3P4P5
No. of oocytes51671114
No. of injected oocytes51171014
No. of embryos425610
No. of embryos transferred32223
Quality of transferred embryos(2×) 4B, 3B(2×) 4B(1×) Early blastocyst, (1×) Morula(2×) Compact morula(3×) 4AB
Fertilization rate (%)8082576071
Clinical pregnancy00000
Live birth00000

4B: 4-cell with grade B; 3B: 3-cell with grade B; 4AB: 4-cell with grade AB

Array CGH profiles of OAT patients (A–D) and different types of aneuploidy in OAT sperm population as assessed by FISH (E–G). A) A genomic profile with complex abnormality for chromosomes −1+3+8–9+10–11+ 13+ 16–18+21 in patient 2. B) Single chromosomal aneuploidy of +20 in patient 3. C) A genomic profile with sex chromosome aneuploidy (Gain of Y) in patient 5. D) A genomic profile with gain of chromosome 19 and sex chromosome aneuploidy (Gain of X/Y) in patient 4. E) Right, a sperm with three signals for chromosome 3 (Red) and normal signal for chromosome 16 (Aqua) and left, a normal sperm with single signals for both chromosomes in patient 2. F) Double disomy for chromosomes 12 (Green) and 20 (Red) and normal signal for chromosome 10 in patient 3. G) Disomy for chromosome 10 (Aqua) and normal signals for chromosomes 12 (Green) and 20 (Red) in patient 3 Array CGH analysis results of OAT patients

Discussion

Sperm aneuploidy occurs for several reasons such as biological, clinical and environmental factors. In this study, an attempt was made to include cases with relatively similar clinical conditions; however, many factors could lead to different aneuploidies in different cases or even different sperm in the same case probably due to effect of multiple components in chromosome-segregation machinery (14). Such differences are also visible in polar bodies and preimplantation embryos (15, 16). Indeed, high-resolution aCGH technique contributed to a better perception of whole genome imbalances with high accuracy. In this study, 2 sperm were simultaneously studied to reduce expenses of aCGH without affecting aneuploidy detection accuracy. Despite a relatively small number of sperm in 5 patients (30 sperm in overall), the explored abnormality was high. Since number of obtained embryos from couples in average is not usually more than 6, as shown in supplementary table 3, studying 6 sperm from each patient could give an average estimation of aneuploidy status. Using aCGH, aberrations in chromosomes 19 and 20 were observed that are not typically studied by FISH studies and abnormalities in these two chromosomes were found in 4 and 2 samples, respectively of two individuals. Extensive information about significant sperm aneuploidy rate in OAT patients, particularly in those with severe abnormal concentration, has been presented by studies that employed FISH (8, 9, 10, 17) but limited capability of this approach for examining large numbers of chromosomes led to insufficient data about complexity of abnormalities in these subjects’ spermatozoa. Differences in types of frequent aneuploid chromosomes at single sperm resolution and total sperm population indicate an error prone segregation for all of chromosomes in OAT rather than germline aneuploidies. Since aneuploidy could occur for all chromosomes even in semen samples of normal individuals with a more or less equal chance, it seems logical to find different chromosomal aneuploidies in study of 6 sperm compared with total population of sperm in the same patient unless in cases with Klinefelter syndrome that carry constitutional sex chromosomal abnormalities (18). In this study, 38.3–81.6% total chromosomal abnormalities were found in spermatozoa from OAT patients which was nearly similar to a 14-chromosome study in OAT (9). Although normal fertile samples were not studied, aneuploidy prevalence in normal fertile men with study of all or large numbers of chromosomes has been reported in a range of 4.5–7.8% (4, 9, 11, 12) that is obviously different from aneuploidy range in OAT. Sex chromosomes studies stated that XY and XX disomy was common in OAT patients (19, 20). In our FISH study, high frequency of XY disomy was observed in 4 of 5 subjects and there were no remarkable differences between the frequency of XX and YY disomy. Also, gain of sex chromosomes was found in 26.6% of samples as assessed by aCGH (Table 2) that indicated high frequency of sex chromosomes’ aberrations in OAT. Despite numerous studies on comprehensive aneuploidy screening in oocytes, few studies were about comprehensive aneuploidy screening in a single sperm by aCGH (11, 12). Recently, next generation sequencing (NGS) method has been utilized for single sperm aneuploidy screening (21, 22). Despite a small number of patients, these studies found a significant percentage of abnormalities compared with normal controls. Although our sample size was also small, regarding the high incidence of aneuploidy in the current comprehensive study and previous evidence from FISH studies, our results might be generalizable to larger populations of OAT; however, further investigation of OAT patients with different inclusion criteria from current study will draw more accurate conclusion. Regarding chromosomal groups, F and G groups, as the smallest chromosomes, were found to be abnormal in aCGH of 4 and 5 patients, respectively (Table 2); this was generally in accordance with FISH results (Supplementary table 2). There are not many publications available for F group, mainly because of FISH limitations but more susceptibility to aneuploidy for G group is clear in sperm studies (4, 8). A negative correlation between chromosome length and meiosis I segregation error has been highlighted (16). To the best of our knowledge, this is the first comprehensive study research investigation of OAT patients with normal karyotypes; moreover, aneuploidy was detected in sperm population by FISH. Some studies elucidated that negative effects of impaired male fertility might lead to chromosomal abnormalities in embryos (23, 24). It should be reminded that follow up of our studied patients revealed no pregnancy after ICSI (Supplementary table 3). A recent 18-year retrospective study reported the highest aneuploidy rate in OAT patients among patients with abnormal semen parameters. This study compared live birth rate in patients with abnormal sperm FISH result with/without PGT-A and revealed an obvious increase of live birth rate following PGT-A (25).

Conclusion

In conclusion, frequency of aneuploidies found by both aCGH and FISH techniques was considerable in OAT sperm. Aneuploidies of the single sperm seem to be somewhat independent of frequent aneuploidies in total sperm population. Considering remarkable aneuploidy revealed in the current study and previous evidence from FISH studies, comprehensive PGT-A in OATs specifically in those with a history of implantation failure might be beneficial for transfer of chromosomally normal embryo.
  23 in total

1.  Detection of aneuploidy in human interphase spermatozoa by fluorescence in situ hybridization (FISH).

Authors:  R H Martin; E Ko; K Chan
Journal:  Cytogenet Cell Genet       Date:  1993

Review 2.  Chromosomal disorders and male infertility.

Authors:  Gary L Harton; Helen G Tempest
Journal:  Asian J Androl       Date:  2011-11-28       Impact factor: 3.285

3.  Incidence of sperm chromosomal abnormalities in a risk population: relationship with sperm quality and ICSI outcome.

Authors:  C Rubio; M Gil-Salom; C Simón; F Vidal; L Rodrigo; Y Mínguez; J Remohí; A Pellicer
Journal:  Hum Reprod       Date:  2001-10       Impact factor: 6.918

4.  Sperm chromosomal abnormalities and their contribution to human embryo aneuploidy.

Authors:  Lorena Rodrigo; Marcos Meseguer; Emilia Mateu; Amparo Mercader; Vanessa Peinado; Lorena Bori; Inmaculada Campos-Galindo; Miguel Milán; Sandra García-Herrero; Carlos Simón; Carmen Rubio
Journal:  Biol Reprod       Date:  2019-12-24       Impact factor: 4.285

5.  Aneuploidy frequencies in semen fractions from ten oligoasthenoteratozoospermic patients donating sperm for intracytoplasmic sperm injection.

Authors:  J Pfeffer; M G Pang; S F Hoegerman; C J Osgood; M W Stacey; J Mayer; S Oehninger; W G Kearns
Journal:  Fertil Steril       Date:  1999-09       Impact factor: 7.329

6.  Sperm aneuploidy in infertile men.

Authors:  A E Calogero; N Burrello; A De Palma; N Barone; R D'Agata; E Vicari
Journal:  Reprod Biomed Online       Date:  2003 Apr-May       Impact factor: 3.828

7.  Frequency of sex chromosomal disomy in spermatozoa of normal and oligozoospermic Iranian patients and its effects on fertilisation and implantation rates after ICSI.

Authors:  P Ghoraeian; Hossein Mozdarani; A Aleyasin; H Alizadeh-Nili
Journal:  Andrologia       Date:  2012-05-08       Impact factor: 2.775

8.  Maternal age, morphology, development and chromosome abnormalities in over 6000 cleavage-stage embryos.

Authors:  S Munné; S Chen; P Colls; J Garrisi; X Zheng; N Cekleniak; M Lenzi; P Hughes; J Fischer; M Garrisi; G Tomkin; J Cohen
Journal:  Reprod Biomed Online       Date:  2007-05       Impact factor: 3.828

9.  Molecular karyotyping of single sperm with nuclear vacuoles identifies more chromosomal abnormalities in patients with testiculopathy than fertile controls: implications for ICSI.

Authors:  Andrea Garolla; Barbara Sartini; Ilaria Cosci; Damiano Pizzol; Marco Ghezzi; Alessandro Bertoldo; Massimo Menegazzo; Elena Speltra; Alberto Ferlin; Carlo Foresta
Journal:  Hum Reprod       Date:  2015-09-23       Impact factor: 6.918

10.  Molecular karyotyping of human single sperm by array- comparative genomic hybridization.

Authors:  Cristina Patassini; Andrea Garolla; Alberto Bottacin; Massimo Menegazzo; Elena Speltra; Carlo Foresta; Alberto Ferlin
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.